ZA200609012B - 4-phenylamino-quinazolin-6-yl-amides - Google Patents

4-phenylamino-quinazolin-6-yl-amides

Info

Publication number
ZA200609012B
ZA200609012B ZA200609012A ZA200609012A ZA200609012B ZA 200609012 B ZA200609012 B ZA 200609012B ZA 200609012 A ZA200609012 A ZA 200609012A ZA 200609012 A ZA200609012 A ZA 200609012A ZA 200609012 B ZA200609012 B ZA 200609012B
Authority
ZA
South Africa
Prior art keywords
quinazolin
phenylamino
amides
Prior art date
Application number
ZA200609012A
Other languages
English (en)
Inventor
Fakhoury Stephen Alan
Reed Jessica Elizabeth
Sexton Karen Elaine
Winters Roy Thomas
Lee Helen Tsenwhei
Kevin Matthew Schlosser
Haile Tecle
Original Assignee
Warner Lambrecht Company Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34965519&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200609012(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambrecht Company Llc filed Critical Warner Lambrecht Company Llc
Publication of ZA200609012B publication Critical patent/ZA200609012B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA200609012A 2004-05-06 2006-10-30 4-phenylamino-quinazolin-6-yl-amides ZA200609012B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US56887204P 2004-05-06 2004-05-06

Publications (1)

Publication Number Publication Date
ZA200609012B true ZA200609012B (en) 2008-06-25

Family

ID=34965519

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200609012A ZA200609012B (en) 2004-05-06 2006-10-30 4-phenylamino-quinazolin-6-yl-amides

Country Status (47)

Country Link
US (3) US7772243B2 (Direct)
EP (1) EP1746999B1 (Direct)
JP (2) JP4205757B2 (Direct)
KR (2) KR100885835B1 (Direct)
CN (1) CN1972688B (Direct)
AP (1) AP2204A (Direct)
AR (1) AR048652A1 (Direct)
AT (1) ATE533490T1 (Direct)
AU (1) AU2005239878B9 (Direct)
BE (1) BE2019C540I2 (Direct)
BR (1) BRPI0510604B8 (Direct)
CA (1) CA2565812C (Direct)
CR (1) CR8727A (Direct)
CY (2) CY1112127T1 (Direct)
DK (1) DK1746999T3 (Direct)
EA (1) EA011237B1 (Direct)
EC (1) ECSP066976A (Direct)
ES (1) ES2374553T3 (Direct)
FR (1) FR19C1052I2 (Direct)
GE (1) GEP20084551B (Direct)
GT (1) GT200500103A (Direct)
HN (1) HN2005000192A (Direct)
HR (1) HRP20110958T1 (Direct)
HU (1) HUS1900039I1 (Direct)
IL (1) IL178822A (Direct)
LT (1) LTC1746999I2 (Direct)
LU (1) LUC00127I2 (Direct)
MA (1) MA28632B1 (Direct)
ME (1) ME01267B (Direct)
MX (1) MXPA06012756A (Direct)
MY (1) MY143566A (Direct)
NI (1) NI200600262A (Direct)
NL (1) NL1028967C2 (Direct)
NO (2) NO339692B1 (Direct)
NZ (1) NZ550796A (Direct)
PA (1) PA8631901A1 (Direct)
PE (1) PE20060215A1 (Direct)
PL (1) PL1746999T3 (Direct)
PT (1) PT1746999E (Direct)
RS (1) RS52119B (Direct)
SI (1) SI1746999T1 (Direct)
TN (1) TNSN06360A1 (Direct)
TW (1) TWI334865B (Direct)
UA (1) UA85706C2 (Direct)
UY (1) UY28885A1 (Direct)
WO (1) WO2005107758A1 (Direct)
ZA (1) ZA200609012B (Direct)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS52119B (sr) * 2004-05-06 2012-08-31 Warner-Lambert Company Llc 4-fenilamino-hinazolin-6-il-amidi
KR100735639B1 (ko) 2004-12-29 2007-07-04 한미약품 주식회사 암세포 성장 억제 효과를 갖는 퀴나졸린 유도체 및 이의제조방법
KR100929146B1 (ko) 2006-06-28 2009-12-01 한미약품 주식회사 암세포 성장 억제 효과를 갖는 퀴나졸린 유도체
NZ595206A (en) 2009-03-11 2014-02-28 Auckland Uniservices Ltd Prodrug forms of kinase inhibitors and their use in therapy
CN102146059A (zh) * 2010-02-08 2011-08-10 上海艾力斯医药科技有限公司 喹唑啉衍生物、制备方法及其应用
CN102382065B (zh) * 2010-08-30 2014-05-28 山东轩竹医药科技有限公司 苯胺取代的喹唑啉衍生物
CN102382106A (zh) 2010-08-30 2012-03-21 黄振华 苯胺取代的喹唑啉衍生物
CN102452989B (zh) * 2010-10-19 2014-10-22 山东轩竹医药科技有限公司 苯胺取代的喹唑啉衍生物
US8828391B2 (en) 2011-05-17 2014-09-09 Boehringer Ingelheim International Gmbh Method for EGFR directed combination treatment of non-small cell lung cancer
JP5859118B2 (ja) * 2011-05-26 2016-02-10 山東軒竹医薬科技有限公司 チロシンキナーゼ阻害剤としてのキナゾリン誘導体、その調製方法及びその使用
CN102838590B (zh) * 2011-06-21 2014-07-09 苏州迈泰生物技术有限公司 氨基喹唑啉衍生物及其在制备抗恶性肿瘤药物中的用途
JP2014532063A (ja) * 2011-10-12 2014-12-04 テリジェン リミテッドＴｅｌｉｇｅｎｅ Ｌｔｄ キナーゼ阻害剤としてのキナゾリン誘導体およびその使用方法
EP2805940B1 (en) 2012-01-17 2016-11-23 Astellas Pharma Inc. Pyrazine carboxamide compound
JP2015515995A (ja) 2012-05-07 2015-06-04 テリジェン リミテッドＴｅｌｉｇｅｎｅ Ｌｔｄ キナーゼ阻害剤として有用な置換アミノキナゾリン
US9556191B2 (en) 2013-04-28 2017-01-31 Sunshine Lake Pharma Co., Ltd. Aminoquinazoline derivatives and their salts and methods of use thereof
CN103288759B (zh) * 2013-05-16 2015-05-20 苏州明锐医药科技有限公司 达克米替尼的制备方法
CN103288758B (zh) * 2013-05-16 2015-01-21 苏州明锐医药科技有限公司 一种达克米替尼的制备方法
JP6139782B2 (ja) 2013-05-21 2017-05-31 チャンスー メドリューション リミテッド 置換ピラゾロピリミジン化合物、及びその薬学的に許容される塩、並びにこれらの溶媒和物、立体異性体、及び互変異性体、並びにこれらを含む医薬組成物
CN103304492B (zh) * 2013-06-20 2015-12-23 湖南欧亚生物有限公司 一种EGFR抑制剂Dacomitinib的合成方法
US9714235B2 (en) * 2013-07-18 2017-07-25 Shanghai Fochon Pharmaceutical Co., Ltd. Quinazoline derivatives, compositions thereof, and use as pharmaceuticals
CN105859641B (zh) * 2015-05-05 2018-11-16 杭州华东医药集团新药研究院有限公司 喹唑啉巴豆基化合物二马来酸盐的晶体及其制备方法和用途
AU2017204973A1 (en) * 2016-01-06 2018-07-12 Trillium Therapeutics Inc. Novel fluorinated quinazoline derivatives as EGFR inhibitors
CN107721986A (zh) * 2016-08-12 2018-02-23 山东轩竹医药科技有限公司 喹唑啉类酪氨酸激酶抑制剂的晶型
CN107721987A (zh) * 2016-08-12 2018-02-23 山东轩竹医药科技有限公司 喹唑啉类酪氨酸激酶抑制剂的晶型
CN107721985A (zh) * 2016-08-12 2018-02-23 山东轩竹医药科技有限公司 喹唑啉类酪氨酸激酶抑制剂的晶型
CN107793368B (zh) * 2016-08-31 2021-10-15 四川科伦药物研究院有限公司 达可替尼溶剂化物、其新晶型及其制备方法和用途
KR102213040B1 (ko) * 2017-12-20 2021-02-05 한국원자력의학원 방사선 손상 보호 또는 완화, 및 폐섬유화 예방 또는 치료 용도
CN109438423A (zh) * 2018-09-12 2019-03-08 通化师范学院 一种肺癌靶向化合物azd-3759的合成工艺的新方法
SG11202102981SA (en) 2018-09-25 2021-04-29 Black Diamond Therapeutics Inc Quinazoline derivatives as tyrosine kinase inhibitor, compositions, methods of making them and their use
CN113195000A (zh) 2018-12-21 2021-07-30 第一三共株式会社 抗体-药物缀合物和激酶抑制剂的组合
KR20210144844A (ko) 2019-03-29 2021-11-30 아스트라제네카 아베 비-소세포 폐암의 치료에 사용하기 위한 오시머티닙
AU2020328598A1 (en) 2019-08-15 2022-03-03 Black Diamond Therapeutics, Inc. Alkynyl quinazoline compounds
WO2021094379A1 (en) 2019-11-12 2021-05-20 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
CN113045541A (zh) * 2019-12-27 2021-06-29 广东东阳光药业有限公司 Egfr抑制剂新晶型及其制备方法
JP2023510426A (ja) 2020-01-20 2023-03-13 アストラゼネカ・アクチエボラーグ 癌を治療するための上皮細胞増殖因子受容体チロシンキナーゼ阻害剤
CN113717111A (zh) * 2020-05-25 2021-11-30 苏州晶云药物科技股份有限公司 喹唑啉类化合物的晶型及其制备方法
US20210369709A1 (en) 2020-05-27 2021-12-02 Astrazeneca Ab EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER
EP4178571A4 (en) 2020-07-10 2024-07-17 The Regents Of The University Of Michigan GAS41 INHIBITORS AND METHODS OF USE
CN112707869B (zh) * 2020-12-25 2022-03-22 扬子江药业集团有限公司 一种达可替尼杂质及其制备方法
IL315848A (en) 2022-03-31 2024-11-01 Astrazeneca Ab Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in combination with an AKT inhibitor for cancer treatment
WO2023209090A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their application in the treatment of cancer
EP4514793A1 (en) 2022-04-28 2025-03-05 Astrazeneca AB Condensed bicyclic heteroaromatic compounds and their use in the treatment of cancer
WO2023209088A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their use in the treatment of cancer
US20240116926A1 (en) 2022-04-28 2024-04-11 Astrazeneca Ab Heteroaromatic compounds
TW202417040A (zh) 2022-06-27 2024-05-01 瑞典商阿斯特捷利康公司 涉及用於治療癌症的上皮生長因子受體酪胺酸激酶抑制劑之組合

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1340821C (en) 1988-10-06 1999-11-16 Nobuyuki Fukazawa Heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components
MX22406A (es) 1989-09-15 1994-01-31 Pfizer Nuevos derivados de n-aril y n-heteroarilamidas y urea como inhibidores de acil coenzima a: acil transferasa del colesterol (acat).
US5362878A (en) 1991-03-21 1994-11-08 Pfizer Inc. Intermediates for making N-aryl and N-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme A: cholesterol acyl transferase (ACAT)
WO1993003034A1 (en) 1991-07-29 1993-02-18 Warner-Lambert Company Quinazoline derivatives as acetylcholinesterase inhibitors
RU2117664C1 (ru) 1991-08-22 1998-08-20 Варнер-Ламберт Компани Производные тетразолсодержащего амида, смесь их изомеров, отдельные изомеры или фармацевтически приемлемые соли
US5366987A (en) 1991-08-22 1994-11-22 Warner-Lambert Company Isoxazolyl-substituted alkyl amide ACAT inhibitors
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
US5412714A (en) * 1992-02-24 1995-05-02 At&T Corp. Mnemonic and synonymic addressing in a telecommunications system
GB9323290D0 (en) 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
PH31122A (en) 1993-03-31 1998-02-23 Eisai Co Ltd Nitrogen-containing fused-heterocycle compounds.
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
JP2890267B2 (ja) 1994-02-23 1999-05-10 ファイザー インク． ４−ヘテロサイクリル−置換キナゾリン誘導体、その調製法および抗癌剤としてのその使用法
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
TW321649B (Direct) 1994-11-12 1997-12-01 Zeneca Ltd
GB9424233D0 (en) 1994-11-30 1995-01-18 Zeneca Ltd Quinazoline derivatives
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
AU5343096A (en) 1995-04-27 1996-11-18 Zeneca Limited Quinazoline derivatives
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
GB9508537D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
JPH11514361A (ja) 1995-10-16 1999-12-07 藤沢薬品工業株式会社 Ｈ＋−ＡＴＰａｓｅとしての複素環式化合物
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
US5760041A (en) * 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
US6184225B1 (en) 1996-02-13 2001-02-06 Zeneca Limited Quinazoline derivatives as VEGF inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
GB9603097D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline compounds
DE69709319T2 (de) 1996-03-05 2002-08-14 Astrazeneca Ab, Soedertaelje 4-anilinochinazolin derivate
ES2174250T5 (es) * 1996-04-12 2010-04-21 Warner-Lambert Company Llc Inhibidores irreversibles de tirosina quinasas.
GB9607729D0 (en) 1996-04-13 1996-06-19 Zeneca Ltd Quinazoline derivatives
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
WO1998002434A1 (en) 1996-07-13 1998-01-22 Glaxo Group Limited Fused heterocyclic compounds as protein tyrosine kinase inhibitors
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
US6225318B1 (en) 1996-10-17 2001-05-01 Pfizer Inc 4-aminoquinazolone derivatives
WO1998038984A2 (en) 1997-03-05 1998-09-11 Sugen, Inc. Formulations for hydrophobic pharmaceutical agents
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
AR012634A1 (es) 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
CA2288705C (en) 1997-05-06 2008-03-18 American Cyanamid Company Use of quinazoline compounds for the treatment of polycystic kidney disease
US5929080A (en) 1997-05-06 1999-07-27 American Cyanamid Company Method of treating polycystic kidney disease
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
ZA986729B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
US6251912B1 (en) 1997-08-01 2001-06-26 American Cyanamid Company Substituted quinazoline derivatives
KR20010031813A (ko) 1997-11-06 2001-04-16 윌리암 에이취 캘넌, 에곤 이 버그 결장 폴립 치료용 티로신 키나제 억제제로서의 퀴나졸린유도체의 용도
US6323209B1 (en) 1997-11-06 2001-11-27 American Cyanamid Company Method of treating or inhibiting colonic polyps
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
AU4317399A (en) 1998-05-28 1999-12-13 Parker Hughes Institute Quinazolines for treating brain tumor
US6384223B1 (en) 1998-07-30 2002-05-07 American Home Products Corporation Substituted quinazoline derivatives
CN1126743C (zh) 1998-07-30 2003-11-05 惠氏 取代的喹唑啉的衍生物
US6297258B1 (en) 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
EP1117649A1 (en) 1998-09-29 2001-07-25 American Cyanamid Company Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
HUP0104211A3 (en) * 1998-11-19 2003-01-28 Warner Lambert Co N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases and pharmaceutical composition containing it
KR20020068261A (ko) 1999-02-27 2002-08-27 베링거 잉겔하임 파르마 카게 티로신 키나제에 의해 매개되는 신호 변환에 대한 억제효과를 갖는 4-아미노-퀴나졸린 및 퀴놀린 유도체
DE19911509A1 (de) 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
YU13200A (sh) 1999-03-31 2002-10-18 Pfizer Products Inc. Postupci i intermedijeri za dobijanje anti-kancernih jedinjenja
MXPA01012899A (es) 1999-06-21 2002-07-30 Boehringer Ingelheim Pharma Heterociclos biciclicos, medicamentos que contienen estos compuestos, su empleo y procedimientos para su preparacion.
AUPQ113799A0 (en) * 1999-06-22 1999-07-15 University Of Queensland, The A method and device for measuring lymphoedema
CA2380904C (en) 1999-08-12 2009-02-10 American Cyanamid Company Nsaid and efgr kinase inhibitor containing composition for the treatment or inhibition of colonic polyps and colorectal cancer
CN1391561A (zh) 1999-09-21 2003-01-15 阿斯特拉曾尼卡有限公司 喹唑啉化合物和含有喹唑啉化合物的药物组合物
US6664390B2 (en) 2000-02-02 2003-12-16 Warner-Lambert Company Llc Method for the simplified production of (3-chloro-4-fluorophenyl)-[7-(3-morpholin-4-yl-propoxy)-6-nitro-quinazoline-4-yl]-amine or (3-chloro-4-fluorophenyl)-[7-(3-morpholin-4-yl-propoxy)-6-amino-quinazoline-4-yl]-amine
US6384051B1 (en) 2000-03-13 2002-05-07 American Cyanamid Company Method of treating or inhibiting colonic polyps
ATE334973T1 (de) 2000-04-07 2006-08-15 Astrazeneca Ab Chinazolinverbindungen
US6627634B2 (en) 2000-04-08 2003-09-30 Boehringer Ingelheim Pharma Kg Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them
CA2403152C (en) 2000-04-08 2008-10-28 Boehringer Ingelheim Pharma Kg Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
DE10031971A1 (de) 2000-06-30 2002-01-10 Goedecke Ag Polymorphe Formen/Hydrate von N-[4-(3-Chlor-4-fluor-phenylamino)-7-(3-morpholin-4-yl-propoxy)-chinazolin-6-yl]-acrylamid Dihydrochlorid, Verfahren zu ihrer Herstellung sowie die Verwendung derselben zur Herstellung von Medikamenten mit irreversibler Tyrosinkinasehemmwirkung
US6446671B2 (en) * 2000-08-04 2002-09-10 John G. Armenia Double wall safety hose
US6653305B2 (en) 2000-08-26 2003-11-25 Boehringer Ingelheim Pharma Kg Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them
US6617329B2 (en) 2000-08-26 2003-09-09 Boehringer Ingelheim Pharma Kg Aminoquinazolines and their use as medicaments
US6403580B1 (en) 2000-08-26 2002-06-11 Boehringer Ingelheim Pharma Kg Quinazolines, pharmaceutical compositions containing these compounds, their use and processes for preparing them
US20020082270A1 (en) 2000-08-26 2002-06-27 Frank Himmelsbach Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
US6656946B2 (en) 2000-08-26 2003-12-02 Boehringer Ingelheim Pharma Kg Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
US6740651B2 (en) 2000-08-26 2004-05-25 Boehringer Ingelheim Pharma Kg Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
HU230302B1 (hu) 2000-10-20 2015-12-28 Eisai R&D Management Co., Ltd. Nitrogéntartalmú aromás származékok és ezeket tartalmazó gyógyászati készítmények
US20030158196A1 (en) 2002-02-16 2003-08-21 Boehringer Ingelheim Pharma Gmbh Co. Kg Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors
DE10063435A1 (de) * 2000-12-20 2002-07-04 Boehringer Ingelheim Pharma Chinazolinderviate,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US7019012B2 (en) 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
PA8539401A1 (es) 2001-02-14 2002-10-28 Warner Lambert Co Quinazolinas como inhibidores de mmp-13
ATE475652T1 (de) 2001-02-21 2010-08-15 Mitsubishi Tanabe Pharma Corp Chinazolinderivate
WO2002092578A1 (en) 2001-05-14 2002-11-21 Astrazeneca Ab Quinazoline derivatives
WO2002092577A1 (en) 2001-05-14 2002-11-21 Astrazeneca Ab Quinazoline derivatives
GB0118752D0 (en) 2001-08-01 2001-09-26 Pfizer Ltd Process for the production of quinazolines
MXPA04004219A (es) 2001-11-03 2004-09-10 Astrazeneca Ab Derivados de quinazolina como agentes antitumorales.
GB0126433D0 (en) 2001-11-03 2002-01-02 Astrazeneca Ab Compounds
GB0128108D0 (en) 2001-11-23 2002-01-16 Astrazeneca Ab Therapeutic use
EP1448551B1 (en) 2001-11-30 2007-10-31 OSI Pharmaceuticals, Inc. Processes for the preparation of substituted bicyclic derivatives for the treatment of abnormal cell growth
PL373848A1 (en) 2001-12-12 2005-09-19 Pfizer Products Inc. Quinazoline derivatives for the treatment of abnormal cell growth
PL211694B1 (pl) 2001-12-24 2012-06-29 Astrazeneca Ab Podstawiona pochodna chinazoliny, jej zastosowania oraz jej kompozycja farmaceutyczna
DE10204462A1 (de) * 2002-02-05 2003-08-07 Boehringer Ingelheim Pharma Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse
MY135609A (en) 2002-02-26 2008-05-30 Astrazeneca Ab Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative
US7645878B2 (en) 2002-03-22 2010-01-12 Bayer Healthcare Llc Process for preparing quinazoline Rho-kinase inhibitors and intermediates thereof
TW200813014A (en) 2002-03-28 2008-03-16 Astrazeneca Ab Quinazoline derivatives
DE10217689A1 (de) * 2002-04-19 2003-11-13 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, ihre Verwendung und Verfahren zu ihrer Herstellung
US20040044014A1 (en) 2002-04-19 2004-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof
DE10221018A1 (de) * 2002-05-11 2003-11-27 Boehringer Ingelheim Pharma Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie
US20030225079A1 (en) 2002-05-11 2003-12-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH)/prostatic hypertrophy
US20040048887A1 (en) 2002-07-09 2004-03-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors
PA8578001A1 (es) 2002-08-07 2004-05-07 Warner Lambert Co Combinaciones terapeuticas de inhibidores de quinasa de erb b y terapias antineoplasicas
EP1594504A4 (en) 2003-01-23 2008-12-17 T K Signal Ltd NEW IRREVERSIBLE EGF RECEPTOR TYROSINE KINASE INHIBITORS AND THEIR USES FOR THERAPEUTIC AND DIAGNOSTIC PURPOSES
PE20040945A1 (es) * 2003-02-05 2004-12-14 Warner Lambert Co Preparacion de quinazolinas substituidas
US7223749B2 (en) 2003-02-20 2007-05-29 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
BRPI0409233A (pt) 2003-04-09 2006-03-28 Pfizer Prod Inc processos para a preparação de derivados de n-((((piridinilóxi)-fenilaminoquinazolinil)-alil) acetamida e compostos relacionados, bem como intermediários de tais processos e processos para a preparação de tais intermediários
ES2301981T3 (es) 2003-04-16 2008-07-01 Astrazeneca Ab Derivados de quinazolina para el tratamiento del cancer.
RU2328287C2 (ru) 2003-08-18 2008-07-10 Пфайзер Продактс Инк. Схема приема erbb2 противоопухолевых агентов
WO2005040125A1 (en) 2003-10-06 2005-05-06 Gpc Biotech Ag Quinazoline derivatives for the treatment of herpesviral infections
EP1690856A4 (en) 2003-11-28 2007-09-05 Aveo Pharmaceuticals Inc CHINAZOLINE DERIVATIVE AND METHOD FOR THE PRODUCTION THEREOF
RS52119B (sr) * 2004-05-06 2012-08-31 Warner-Lambert Company Llc 4-fenilamino-hinazolin-6-il-amidi

Also Published As

Publication number Publication date
EA011237B1 (ru) 2009-02-27
LTPA2019016I1 (lt) 2019-09-25
LTC1746999I2 (lt) 2020-05-11
NO2019035I1 (no) 2019-09-13
US20100190977A1 (en) 2010-07-29
IL178822A (en) 2013-07-31
NI200600262A (es) 2008-03-07
JP4966923B2 (ja) 2012-07-04
KR100885835B1 (ko) 2009-02-26
LUC00127I2 (fr) 2020-10-06
GT200500103A (es) 2006-01-10
IL178822A0 (en) 2007-03-08
UA85706C2 (en) 2009-02-25
NZ550796A (en) 2010-07-30
NL1028967A1 (nl) 2005-11-08
CA2565812A1 (en) 2005-11-17
HUS1900039I1 (hu) 2019-10-28
FR19C1052I2 (fr) 2020-09-04
AU2005239878A1 (en) 2005-11-17
AU2005239878B9 (en) 2010-01-07
US8466165B2 (en) 2013-06-18
RS52119B (sr) 2012-08-31
KR20080095915A (ko) 2008-10-29
ATE533490T1 (de) 2011-12-15
NO339692B1 (no) 2017-01-23
PE20060215A1 (es) 2006-03-20
EA200601849A1 (ru) 2007-04-27
BRPI0510604A (pt) 2007-10-30
US20130274275A1 (en) 2013-10-17
CY1112127T1 (el) 2015-11-04
HN2005000192A (es) 2010-06-09
WO2005107758A1 (en) 2005-11-17
JP2007536368A (ja) 2007-12-13
MA28632B1 (fr) 2007-06-01
CA2565812C (en) 2012-03-13
SI1746999T1 (sl) 2012-01-31
US7772243B2 (en) 2010-08-10
ES2374553T3 (es) 2012-02-17
MY143566A (en) 2011-05-31
KR20070008683A (ko) 2007-01-17
PA8631901A1 (es) 2005-11-25
LUC00127I1 (fr) 2019-09-19
NL1028967C2 (nl) 2006-06-27
US8623883B2 (en) 2014-01-07
TW200540163A (en) 2005-12-16
GEP20084551B (en) 2008-11-25
ECSP066976A (es) 2006-12-29
EP1746999A1 (en) 2007-01-31
EP1746999B1 (en) 2011-11-16
HRP20110958T1 (hr) 2012-01-31
TNSN06360A1 (fr) 2008-02-22
CR8727A (es) 2006-11-30
AU2005239878B2 (en) 2009-09-03
BRPI0510604B1 (pt) 2020-05-12
HK1106432A1 (en) 2008-03-14
JP2009007363A (ja) 2009-01-15
CN1972688B (zh) 2012-06-27
JP4205757B2 (ja) 2009-01-07
DK1746999T3 (da) 2012-01-23
CY2019034I2 (el) 2019-11-27
FR19C1052I1 (Direct) 2019-10-11
TWI334865B (en) 2010-12-21
BRPI0510604B8 (pt) 2021-05-25
US20050250761A1 (en) 2005-11-10
AP2204A (en) 2011-02-07
BE2019C540I2 (Direct) 2024-08-08
AP2006003810A0 (en) 2006-12-31
MXPA06012756A (es) 2007-01-16
UY28885A1 (es) 2005-12-30
CY2019034I1 (el) 2019-11-27
PT1746999E (pt) 2012-01-11
AR048652A1 (es) 2006-05-10
CN1972688A (zh) 2007-05-30
ME01267B (me) 2013-06-20
NO20065626L (no) 2007-01-23
PL1746999T3 (pl) 2012-07-31

Similar Documents

Publication Publication Date Title
HUS1900039I1 (hu) 4-fenilamino-kinazolin-6-il-amid
DE602005020252D1 (en) Röhrenförmige prothese
EG23651A (en) Culturama
DE602005007474D1 (en) Substituierte morpholin- und thiomorpholinderivate
DE502005007456D1 (en) Nanoemulsionen
DE602005008719D1 (en) Notinformationsschild
DE602005010440D1 (en) Lymerdispersionen
GB0407499D0 (en) Souv-bath
GB0409310D0 (en) Cancap
DE502005006813D1 (en) Common-rail-injektor
GB0400902D0 (en) Monfilaments
GB0406542D0 (en) K-peg
GB0405601D0 (en) Core-house
DE502005004945D1 (en) Auto-splice-system
GB0415611D0 (en) Haemoease
GB0421310D0 (en) Baby-barrow
GB0404045D0 (en) Solidlock
GB0415158D0 (en) Timestick
GB0413709D0 (en) Wigweave
GB0413130D0 (en) Alcolock
GB0418789D0 (en) Fingeeze
GB0419748D0 (en) Dim-1
GB0420472D0 (en) Surefoot
GB0421300D0 (en) Twin-a-chair
GB0427396D0 (en) e-speedreader